FDA Drug recall D-0185-2020
Ranitidine Tablets, USP 150 mg, NDC 57896-717 (GeriCare) OTC
- FDA Drug
- Class II
- completed
- Published 2019-11-13
On 2019-11-13 the FDA classified a Class II recall of Ranitidine Tablets, USP 150 mg, NDC 57896-717 (GeriCare) OTC by Dr Reddy S Laboratories, citing CGMP Deviations: Presence of NDMA impurity detected in product.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0185-2020 |
| Classification | Class II |
| Status | completed |
| Initiated | 2019-10-01 |
| Published | 2019-11-13 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Dr Reddy S Laboratories |
| Distribution | US |
Product
Ranitidine Tablets, USP 150 mg, NDC 57896-717 (GeriCare) OTC
Reason
CGMP Deviations: Presence of NDMA impurity detected in product.
Identifiers
| code_info | Batch Numbers: All lots within expiry. |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: completed.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0185-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.